- Home
- BVFL vs SGMT Comparison
BVFL vs SGMT Comparison
Compare BVFL & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BVFL
- SGMT
- Stock Information
- Founded
- BVFL 1873
- SGMT 2006
- Country
- BVFL United States
- SGMT United States
- Employees
- BVFL N/A
- SGMT N/A
- Industry
- BVFL Savings Institutions
- SGMT
- Sector
- BVFL Finance
- SGMT
- Exchange
- BVFL Nasdaq
- SGMT Nasdaq
- Market Cap
- BVFL 164.8M
- SGMT 165.4M
- IPO Year
- BVFL N/A
- SGMT 2023
- Fundamental
- Price
- BVFL $15.11
- SGMT $4.12
- Analyst Decision
- BVFL
- SGMT Strong Buy
- Analyst Count
- BVFL 0
- SGMT 7
- Target Price
- BVFL N/A
- SGMT $25.71
- AVG Volume (30 Days)
- BVFL 34.6K
- SGMT 877.5K
- Earning Date
- BVFL 01-27-2025
- SGMT 03-24-2025
- Dividend Yield
- BVFL N/A
- SGMT N/A
- EPS Growth
- BVFL N/A
- SGMT N/A
- EPS
- BVFL 1.10
- SGMT N/A
- Revenue
- BVFL $37,904,000.00
- SGMT N/A
- Revenue This Year
- BVFL N/A
- SGMT N/A
- Revenue Next Year
- BVFL N/A
- SGMT N/A
- P/E Ratio
- BVFL $13.74
- SGMT N/A
- Revenue Growth
- BVFL N/A
- SGMT N/A
- 52 Week Low
- BVFL $10.14
- SGMT $2.39
- 52 Week High
- BVFL $18.19
- SGMT $7.64
- Technical
- Relative Strength Index (RSI)
- BVFL 38.39
- SGMT 43.11
- Support Level
- BVFL $15.11
- SGMT $3.96
- Resistance Level
- BVFL $15.47
- SGMT $4.83
- Average True Range (ATR)
- BVFL 0.44
- SGMT 0.38
- MACD
- BVFL 0.05
- SGMT -0.04
- Stochastic Oscillator
- BVFL 34.86
- SGMT 13.39
About BVFL BV Financial Inc.
BV Financial Inc is a federally-chartered savings and loan holding company engaged in offering traditional financial services to consumers and businesses. It offers savings, interest checking, money market, personal and business checking, non-interest checking, education savings, small business checking, business checking as well as certificates of deposit and IRA certificates of deposit. The Company's sources of revenue are derived from interest and dividends earned on loans and investment securities.
About SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company focused on developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. The company's lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH).